Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects.
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long Covid.
John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.